Conatus Pharmaceutic (NASDAQ:CNAT) down -3.76% to close at the price of $0.77. The stock has a market capitalization of $26.55 Million however its outstanding shares are 34.48 Million. The company’s beta value stood at 3.3.

Conatus Pharmaceutic (NASDAQ:CNAT) has an ABR of 3 which is the combined stock view of 3 analysts poll results. As per Zacks simplified descending rating scale the ABR rank is displayed in the range of 1 to 5 where 1 represents Strong Buy and 5 a Strong Sell. As the name implies that ABR will show you the Average of Brokerage Recommendations on a given stock. It helps you quickly get a picture of where Wall Street stands on a stock without reading huge research reports. The smaller number of ABR is the more favorable. The modest value of the stock is known as the current ABR of the stock.

However out of 3 analysts 0 suggest Conatus Pharmaceutic (NASDAQ:CNAT) a Strong Buy, 0 suggested Buy, 3 Hold and 0 Sell, while 0 analysts recommend the stock a Strong Sell.

Taking a broader look at the analyst consensus, brokerage firms have a price target of $1.6 on Conatus Pharmaceutic (NASDAQ:CNAT). Brokerage firms on the street have price targets on the name ranging from $1.5 to $1.7 based on 2 opinions.

Conatus Pharmaceutic (NASDAQ:CNAT) as of current trade, has shown weekly performance of -40.31% which was maintained at -73.36% in one month period. Year to date performance remained at -55.49%. During the past three months the stock gain -57.69%, however six months performance of the stock remained at -84.51%. Conatus Pharmaceutic (NASDAQ:CNAT)’s price sits -58.85% off from its SMA 50 of $1.7828 and -77.36% away from the SMA 200 which is at $2.8097.

Currently Conatus Pharmaceutic (NASDAQ:CNAT)’s shares owned by insiders are 3.34%, whereas shares owned by institutional owners are 24.8%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded 0.12%.

The stock is trading -88.57% away from its 52 week high of $6.74 and 5.48% far from the stock’s low point over the past 52 weeks, which was $0.73.

The price-earnings ratio (P/E ratio) is the ratio for valuing a company that measures its current share price relative to its per-share earnings. Conatus Pharmaceutic (NASDAQ:CNAT)’s price to earnings ratio stood at 0. A high P/E suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E. A low P/E can indicate either that a company may currently be undervalued or that the company is doing exceptionally well relative to its past trends.

The PEG ratio is used to determine a stock’s value while taking the company’s earnings growth into account, and is considered to provide a more complete picture than the P/E. Conatus Pharmaceutic (NASDAQ:CNAT) has a current PEG of 0. Conatus Pharmaceutic (NASDAQ:CNAT)’s price to sales ratio for trailing twelve month stands at 0.79, whereas its price to book ratio for the most recent quarters is at 0.87. However the company’s price to cash per share for most recent quarter stands at 1.18. Its price to free cash flow for trailing twelve months is 0.65.